Picture loading failed.

Pre-Made Fianlimab biosimilar, Whole mAb, Anti-LAG3 Antibody: Anti-CD223 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Fianlimab (previously REGN 3767) is an anti-lymphocyte-activation gene 3 (LAG3) monoclonal antibody, being developed by Regeneron Pharmaceuticals, for the treatment of solid tumours and haematological malignancies.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-210-1mg 1mg 3090
GMP-Bios-ab-210-10mg 10mg Inquiry
GMP-Bios-ab-210-100mg 100mg Inquiry
GMP-Bios-ab-210-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Fianlimab biosimilar, Whole mAb, Anti-LAG3 Antibody: Anti-CD223 therapeutic antibody
INN Name Fianlimab
TargetLAG3
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2019
Year Recommended2020
CompaniesRegeneron Pharmaceuticals
Conditions Approvedna
Conditions ActiveCancer
Conditions Discontinuedna
Development Techna